A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

Inclusion Criteria: * Voluntarily agree to participate and ability to provide informed consent or have duly appointed health care proxy with the authority to consent. * Confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by polymerase chain reaction test or equivalent approved test. * Inpatient hospitalization. * Evidence of SARS-CoV-2 infection with the diagnosis of moderate to severe ARDS per Berlin definition, no more than 2 weeks prior to study enrollment. * Participants, or duly appointed health care proxy with the authority to consent, must consent to placement of a central venous access line for the administration of agenT-797. Exclusion Criteria: * Currently participating and receiving study therapy of an investigational agent that is not registered for any other indication. Note: Participants may receive the standard of care for SARS-CoV-2 infection as per institutional practices. * Presence of comorbidities limiting expected survival of \<1 month. * Any comorbidity which in the opinion of the investigator may preclude/confound study required safety and efficacy assessments. * Clinically significant cardiomyopathy. * Receipt of non-oncology vaccines containing live virus for prevention of infectious diseases within 4 weeks prior to first dose of study treatment. * Known hypersensitivity to natural killer cells or their preservation solution. * Active systemic bacterial or fungal infection or viral co-infection. * Legally i…